The medications used for MS act on cell-mediated immunity, most likely associated with disease activation or progression.12For instance, fingolimod, a modulator of sphingosine-1-phosphate receptors, may trigger TB reactivation by sequestering lymphocytes in lymphoid tissue. Here, S1PR1 is linked to tuberculosis.